BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Durvalumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Durvalumab\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02962063-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT02962063)
DESCRIPTION:Durvalumab\, phase 1/2.\nStudy: Durvalumab\, an Anti-PDLI Antib
 ody\, and Tremelimumab\, an Anti-CTLA4 Antibody\, and Chemoradiation Befor
 e Surgery for Esophageal Cancer\nEstimated primary completion: November 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT02962063
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05856695-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05856695)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-d
 isease Small-sell Lung Cancer (SCLC)\nEstimated primary completion: Novemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05856
 695
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03158064-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03158064)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Evaluating Immune Therapy\, Durav
 alumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumo
 rs\nEstimated primary completion: November 2026. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03158064
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06058663-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Durvalumab: Phase 1 readout est. (NCT06058663)
DESCRIPTION:Durvalumab\, phase 1.\nStudy: Radioembolization With Tremelimum
 ab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic In
 trahepatic Cholangiocarcinoma\nEstimated primary completion: 30 November 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT06058663
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06070740-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06070740)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: First- Line Treatment With Durval
 umab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine C
 arcinoma\nEstimated primary completion: 30 November 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06070740
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07081633-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07081633)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab and Tremelimumab With Lenvatinib as First-line Treatment in Patients 
 With Unresectable Hepatocellular Carcinoma\nEstimated primary completion: 
 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dur
 valumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07081633
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02826434-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 1 readout est. (NCT02826434)
DESCRIPTION:Durvalumab\, phase 1.\nStudy: Adjuvant PVX-410 Vaccine and Durv
 alumab in Stage II/III Triple Negative Breast Cancer\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT02826434
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04900818-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 1 readout est. (NCT04900818)
DESCRIPTION:Durvalumab\, phase 1\, Biliary Tract Cancer.\nStudy: Study of T
 J033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors\
 nEstimated primary completion: December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT04900818
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05927142-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT05927142)
DESCRIPTION:Durvalumab\, phase 1/2.\nStudy: Combining Anti-PD-L1 Immune Che
 ckpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients W
 ith Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy\nEsti
 mated primary completion: December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05927142
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05000710-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05000710)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Conc
 omitant Radiotherapy\, Tremelimumab & Durvalumab for Advanced NSCLC Patien
 ts Progressing on First-line Immunotherapy\nEstimated primary completion: 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durval
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05000710
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03740893-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03740893)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: PHOENIX DDR/Anti-PD-L1 Trial: A P
 re-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Stu
 dy of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunother
 apy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negat
 ive Breast Cancer\nEstimated primary completion: December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03740893
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05620628-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05620628)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Ph2 Study of Savolitinib and Durv
 alumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIK
 TORY-2)\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05620628
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03965468-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03965468)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Immu
 notherapy\, Chemotherapy\, Radiotherapy and Surgery for Synchronous Oligo-
 metastatic NSCLC\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03965468
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04116047-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04116047)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: CompARE: Escalating Treatment of 
 Intermediate and High-risk Oropharyngeal Cancer (OPC)\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT04116047
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585490-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04585490)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Adap
 tive ctDNA-Based Personalization of Treatment During Consolidation Therapy
  in NSCLC\nEstimated primary completion: December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04585490
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05655949-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05655949)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Y-90 With Durvalumab/Gem/Cis in I
 ntrahepatic Cholangio\nEstimated primary completion: 1 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05655949
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04245514-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261207
DTEND;VALUE=DATE:20261208
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04245514)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Mult
 imodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)\nEstim
 ated primary completion: 7 December 2026. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04245514
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06908070-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:Durvalumab: Phase 4 readout est. (NCT06908070)
DESCRIPTION:Durvalumab\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Chem
 oradiotherapy With Surgery Followed by Consolidation Durvalumab\nEstimated
  primary completion: 17 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06908070
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06490107-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06490107)
DESCRIPTION:Durvalumab\, phase 2\, Biliary Tract Cancer.\nStudy: Durvalumab
  Combined With S-1 as Adjuvant Therapy of Resectable BTC\nEstimated primar
 y completion: 30 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06490107
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03606967-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03606967)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Testing the Addition of an Indivi
 dualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patien
 ts With Metastatic Triple Negative Breast Cancer\nEstimated primary comple
 tion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03606967
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03772561-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 1 readout est. (NCT03772561)
DESCRIPTION:Durvalumab\, phase 1.\nStudy: Phase I Study of AZD5363 + Olapar
 ib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malign
 ancies\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03772561
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05136846-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 1 readout est. (NCT05136846)
DESCRIPTION:Durvalumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Papa
 verine in Combination With Chemoradiation for the Treatment of Stage II-II
 I Non-small Cell Lung Cancer\nEstimated primary completion: 31 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05136846
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04462328-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 1 readout est. (NCT04462328)
DESCRIPTION:Durvalumab\, phase 1.\nStudy: Acalabrutinib and Durvalumab in P
 rimary and Secondary Central Nervous System Lymphoma\nEstimated primary co
 mpletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04462328
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03594396-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03594396)
DESCRIPTION:Durvalumab\, phase 1/2.\nStudy: Window of Opportunity Trial of 
 Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast 
 Cancer\nEstimated primary completion: 31 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03594396
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06418087-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06418087)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Durvalumab With Carboplatin and E
 toposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LC
 NEC)\nEstimated primary completion: 31 December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06418087
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844046-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05844046)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Sequen
 tial or Up-front Triple Treatment With Durvalumab\, Tremelimumab and Bevac
 izumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients\nEstimat
 ed primary completion: 31 December 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05844046
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04602533-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04602533)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Efficacy
  and Safety of Standard of Care Plus Durvalumab in Patients With Limited D
 isease Small Cell Lung Cancer (DOLPHIN)\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durval
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04602533
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04230759-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04230759)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Radiochemotherapy +/- Durvalumab 
 for Locally-advanced Anal Carcinoma. A Multicenter\, Randomized\, Phase II
  Trial of the German Anal Cancer Study Group\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 urvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04230759
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937830-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03937830)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Combin
 ed Treatment of Durvalumab\, Bevacizumab\, Tremelimumab and Transarterial 
 Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Bili
 ary Tract Carcinoma\nEstimated primary completion: 31 December 2026. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03937830
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06698250-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06698250)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Zanzal
 intinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatoce
 llular Carcinoma (ZENOBIA)\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06698250
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04918186-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04918186)
DESCRIPTION:Durvalumab\, phase 2\, Ovarian Cancer.\nStudy: Immunotherapy Pl
 atform Study in Platinum Resistant High Grade Serous Ovarian Cancer\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT04918186
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05303532-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05303532)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: Roll Over StudY for Patients Who 
 Have Completed a Previous Oncology Study With Durvalumab\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05303532
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824363-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Durvalumab: Phase 1 readout est. (NCT06824363)
DESCRIPTION:Durvalumab\, phase 1.\nStudy: ProofPrincip IntraTu TCells Singl
 DoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu\nEstima
 ted primary completion: January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06824363
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05206812-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05206812)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Wind
 ow of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynami
 cs in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)\nEstimated pri
 mary completion: January 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05206812
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04699838-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04699838)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Chemo-Im
 munotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Pa
 tients With Extensive Stage Small Cell Lung Cancer\nEstimated primary comp
 letion: January 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04699838
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06440993-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06440993)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Durvalumab + Intraductal Radiofre
 quency Ablation (ID-RFA) in Extra- and Intrahepatic Cholangiocarcinoma\nEs
 timated primary completion: January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06440993
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679399-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07679399)
DESCRIPTION:Durvalumab\, phase 2\, Biliary Tract Cancer.\nStudy: A Phase II
  Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed
  by Lenvatinib Versus Capecitabine in Biliary Tract Cancer.\nEstimated pri
 mary completion: 1 January 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07679399
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05713838-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05713838)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Organ Preservation With Durvaluma
 b-based Immunotherapy in Combination With Chemoradiation as Definitive The
 rapy for Early Stage Esophageal Adenocarcinoma With Indication for Radical
  Surgery\nEstimated primary completion: 1 January 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05713838
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03851614-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03851614)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Study of DNA Damage\, Angiogenesi
 s\, and PD-L1 Inhibitors in Advanced Solid Tumors\nEstimated primary compl
 etion: 1 January 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03851614
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05374603-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05374603)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Savo
 litinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Meta
 static NSCLC\nEstimated primary completion: 18 January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05374603
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03601455-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03601455)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Radiation Therap
 y and Durvalumab With or Without Tremelimumab in Treating Participants Wit
 h Unresectable\, Locally Advanced\, or Metastatic Bladder Cancer\nEstimate
 d primary completion: 31 January 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03601455
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04499053-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04499053)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Durv
 alumab and Tremelimumab in Combination With Chemotherapy in HIV-infected P
 atients With Non-small Cell Lung Cancer\nEstimated primary completion: Feb
 ruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvaluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 499053
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04716946-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04716946)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Trea
 ting Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation 
 Therapy\nEstimated primary completion: February 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04716946
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05696782-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05696782)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Quic
 k Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lu
 ng Cancer\nEstimated primary completion: February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05696782
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04605731-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Durvalumab: Phase 1 readout est. (NCT04605731)
DESCRIPTION:Durvalumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Durval
 umab and Tremelimumab After Radioembolization for the Treatment of Unresec
 table\, Locally Advanced Liver Cancer\nEstimated primary completion: 23 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4605731
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06223711-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06223711)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiothe
 rapy in Oligometastatic ES-SCLC\nEstimated primary completion: March 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06223711
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03983954-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Durvalumab: Phase 1 readout est. (NCT03983954)
DESCRIPTION:Durvalumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Napt
 umomab Estafenatox in Combination With Durvalumab in Subjects With Selecte
 d Advanced or Metastatic Solid Tumor\, Including a Cohort Expansion in Eso
 phageal Cancer.\nEstimated primary completion: 1 March 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03983954
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04106115-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT04106115)
DESCRIPTION:Durvalumab\, phase 1/2\, Bladder Cancer.\nStudy: DURvalumab in 
 Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder 
 CancEr\nEstimated primary completion: 30 March 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT04106115
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05422690-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05422690)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: The Purpose of This Research Stud
 y is to See if Combining Gemcitabine\, Cisplatin and Durvalumab Chemothera
 py Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Bet
 ter Together to Shrink Tumors and Control Cancer\nEstimated primary comple
 tion: 30 March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05422690
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04387084-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Durvalumab: Phase 1 readout est. (NCT04387084)
DESCRIPTION:Durvalumab\, phase 1.\nStudy: Short-term Fasting Prior to PD-1/
 PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy\nEst
 imated primary completion: 31 March 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04387084
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768570-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03768570)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Trimodality Ther
 apy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Can
 cer\nEstimated primary completion: 31 March 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03768570
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175441-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07175441)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Evalua
 tion of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Partic
 ipants With Advanced Unresectable Hepatocellular Carcinoma\nEstimated prim
 ary completion: April 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07175441
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03694236-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03694236)
DESCRIPTION:Durvalumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Co
 ncurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resec
 table Stage III NSCLC\nEstimated primary completion: May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03694236
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Pre-operative Targeted Treatments
  in Molecularly Selected Resectable Colorectal Cancer (UNICORN)\nEstimated
  primary completion: May 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06375915-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06375915)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Precision Medicine in Patients Wi
 th Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biologi
 cal Therapy\nEstimated primary completion: May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06375915
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855225-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06855225)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: A Phase II Study of Single Tremel
 imumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in 
 Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangio
 carcinoma\nEstimated primary completion: May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06855225
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548412-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06548412)
DESCRIPTION:Durvalumab\, phase 1/2\, Biliary Tract Cancer.\nStudy: CTX-009 
 With Gemcitabine\, Cisplatin\, and Durvalumab as First-line Therapy in Pat
 ients With Unresectable or Metastatic Biliary Tract Cancers\nEstimated pri
 mary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06548412
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451043-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05451043)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab and Tremelimumab in Combination With Propranolol and Chemotherapy for
  Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)\nEstimated pr
 imary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05451043
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04379596-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04379596)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Ph1b/2 Study of the Safety and Ef
 ficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (D
 ESTINY-Gastric03)\nEstimated primary completion: 4 May 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04379596
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05886439-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT05886439)
DESCRIPTION:Durvalumab\, phase 1/2.\nStudy: LK101 Combined With PD-1 or PD-
 L1 Monoclonal Antibody in the Treatment of Lung Cancer\nEstimated primary 
 completion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05886439
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733689-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 1 readout est. (NCT05733689)
DESCRIPTION:Durvalumab\, phase 1.\nStudy: Response Adapted Neoadjuvant Ther
 apy in Gastroesophageal Cancers (RANT-GC Trial)\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durva
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05733689
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05742607-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05742607)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: IPH5
 201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer 
 (MATISSE)\nEstimated primary completion: June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05742607
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063565-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05063565)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: TheraS
 phere With Durvalumab and Tremelimumab for HCC\nEstimated primary completi
 on: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durval
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05063565
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06470256-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Durvalumab: Phase 1 readout est. (NCT06470256)
DESCRIPTION:Durvalumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Pallia
 tive Hepatectomy Combined With Targeted Therapy and Immunotherapy for Adva
 nced Hepatocellular Carcinoma\nEstimated primary completion: 1 June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06470256
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619313-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Durvalumab: Phase 1 readout est. (NCT07619313)
DESCRIPTION:Durvalumab\, phase 1.\nStudy: AB801 in Combination With Chemoth
 erapy and Immunotherapy for the Treatment of Patients With Borderline Rese
 ctable\, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic C
 ancer\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07619313
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03907475-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03907475)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Durvalumab in Combination With Ch
 emotherapy in Treating Patients With Advanced Solid Tumors\, DURVA+ Trial\
 nEstimated primary completion: 1 June 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03907475
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796114-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Durvalumab: Phase na readout est. (NCT06796114)
DESCRIPTION:Durvalumab\, phase na\, Hepatocellular Carcinoma.\nStudy: Ident
 ification of Innovative Biomarkers to Predict Outcomes in Hepatocellular C
 arcinoma Treated With Tremelimumab and Durvalumab\nEstimated primary compl
 etion: 25 June 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06796114
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04686305-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 1 readout est. (NCT04686305)
DESCRIPTION:Durvalumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Withou
 t Chemotherapy in Advanced or Metastatic HER2+\, Non-squamous NSCLC\nEstim
 ated primary completion: 30 June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04686305
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04668300-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04668300)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Oleclumab and Durvalumab for the 
 Treatment of Recurrent\, Refractory\, or Metastatic Sarcoma\nEstimated pri
 mary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04668300
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05198830-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05198830)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Test
 ing the Addition of an Anti-Cancer Drug\, TRC102\, to the Usual Chemothera
 py Treatment (Pemetrexed\, Cisplatin or Carboplatin) During Radiation Ther
 apy for Stage III Non-Squamous Non-Small Cell Lung Cancer\nEstimated prima
 ry completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05198830
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04550260-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04550260)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: Study of Durvalumab Versus Placeb
 o in Combination With Definitive Chemoradiation Therapy in Patient With ES
 CC\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04550260
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06728410-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06728410)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: A Phase II Study of Pemigatinib P
 lus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcin
 oma Patients With FGFR-2 Fusion or Rearrangement\nEstimated primary comple
 tion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durv
 alumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06728410
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06103864-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06103864)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: A Phase III Study of Dato-DXd Wit
 h or Without Durvalumab Compared With Investigator's Choice of Chemotherap
 y in Combination With Pembrolizumab in Patients With PD-L1 Positive Locall
 y Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIO
 N-Breast05)\nEstimated primary completion: 28 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06103864
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06290505-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06290505)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: A Trial of Palliative Chemotherap
 y\, Radiation and Immune Treatment for Oesophageal Cancer: PALEO Study\nEs
 timated primary completion: 31 July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06290505
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04522544-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04522544)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage
  HCC\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04522544
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06263153-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06263153)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Futibatinib in C
 ombination With Durvalumab Prior to Cystectomy for the Treatment of Muscle
 -Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based T
 herapy\nEstimated primary completion: 31 July 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06263153
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511504-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07511504)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Y-90 R
 adioembolization\, Durvalumab\, Tremelimumab\, and Zanzalintinib for the T
 reatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma\nEs
 timated primary completion: 1 August 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07511504
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04169841-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04169841)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Study Evaluating the Efficacy of 
 a Double Immunotherapy Combined With Olaparib in Patients With Solid Cance
 rs and Carriers of Homologous Recombination Repair Genes After Olaparib Tr
 eatment\nEstimated primary completion: 10 August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04169841
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391670-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Durvalumab: Phase 1 readout est. (NCT07391670)
DESCRIPTION:Durvalumab\, phase 1.\nStudy: A Phase I Dose Escalation and Dos
 e Expansion Study to Investigate the Pharmacokinetics and Safety of Subcut
 aneous Durvalumab\nEstimated primary completion: 30 August 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07391670
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04465968-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04465968)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Effi
 cacy and Safety of CRT\, Durvalumab and Surgery for SST\nEstimated primary
  completion: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04465968
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03245541-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03245541)
DESCRIPTION:Durvalumab\, phase 1/2.\nStudy: Radiation Therapy in Combinatio
 n With Durvalumab for People With Pancreatic Cancer\nEstimated primary com
 pletion: September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03245541
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Durvalumab: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: The Drug Rediscovery Protocol (DR
 UP Trial)\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07853690-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Durvalumab: Phase na readout est. (NCT07853690)
DESCRIPTION:Durvalumab\, phase na\, Biliary Tract Cancer.\nStudy: Histotrip
 sy in Biliary Tract Cancer\nEstimated primary completion: September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07853690
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629585-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05629585)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: A Study of Dato-DXd With or Witho
 ut Durvalumab Versus Investigator's Choice of Therapy in Patients With Sta
 ge I-III Triple-negative Breast Cancer Without Pathological Complete Respo
 nse Following Neoadjuvant Therapy (TROPION-Breast03)\nEstimated primary co
 mpletion: 1 September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05629585
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06501625-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270913
DTEND;VALUE=DATE:20270914
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06501625)
DESCRIPTION:Durvalumab\, phase 1/2.\nStudy: Ivosidenib Plus Durvalumab and 
 Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally A
 dvanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation\nEstimated 
 primary completion: 13 September 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06501625
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045975-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270927
DTEND;VALUE=DATE:20270928
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06045975)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC
  Treated by by Percutaneous Ablation Procedure\nEstimated primary completi
 on: 27 September 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06045975
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05796089-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05796089)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Chemothe
 rapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thor
 acic Radiotherapy\nEstimated primary completion: 30 September 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05796089
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04397003-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04397003)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Personal
 ized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Exten
 sive Stage Small Cell Lung Cancer\nEstimated primary completion: 30 Septem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0439
 7003
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04628767-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Durvalumab: Phase 2/3 readout est. (NCT04628767)
DESCRIPTION:Durvalumab\, phase 2/3\, Urothelial Carcinoma.\nStudy: Testing 
 the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for P
 atients With High-Grade Upper Urinary Tract Cancer\nEstimated primary comp
 letion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04628767
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05701488-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Durvalumab: Phase 1 readout est. (NCT05701488)
DESCRIPTION:Durvalumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: SIRT W
 ith Tremelimumab and Durvalumab for Resectable HCC\nEstimated primary comp
 letion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05701488
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526104-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06526104)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study 
 of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellu
 lar Carcinomas With Child-Pugh-B Cirrhosis\nEstimated primary completion: 
 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durva
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06526104
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05068232-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05068232)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab and Ablative Radiation in Small Cell Lung Cancer (DARES)\nEstimated pri
 mary completion: 1 October 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05068232
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06484491-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Durvalumab: Phase na readout est. (NCT06484491)
DESCRIPTION:Durvalumab\, phase na\, Non-Small Cell Lung Cancer.\nStudy: IMP
 T Dose Escalation for NSCLC (HyDose)\nEstimated primary completion: 1 Octo
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0648
 4491
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027436-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Durvalumab: Phase 3 readout est. (NCT07027436)
DESCRIPTION:Durvalumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Radiat
 ion Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surgery
  Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellula
 r Carcinoma.\nEstimated primary completion: 12 October 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07027436
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02484404-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT02484404)
DESCRIPTION:Durvalumab\, phase 1/2.\nStudy: Phase I/II Study of the Anti-Pr
 ogrammed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With
  Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recur
 rent Ovarian\, Triple Negative Breast\, Lung\, Prostate and Colorectal Can
 ...\nEstimated primary completion: 30 October 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT02484404
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04940286-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04940286)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Gemcitabine\, Nab-paclitaxel\, Du
 rvalumab\, and Oleclumab Before Surgery for the Treatment of in Resectable
 /Borderline Resectable Primary Pancreatic Cancer\nEstimated primary comple
 tion: 30 October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04940286
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05687266-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05687266)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e III\, Open-label\, First-line Study of Dato-DXd in Combination With Durv
 alumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alter
 ations\nEstimated primary completion: 1 November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05687266
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06546969-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 1 readout est. (NCT06546969)
DESCRIPTION:Durvalumab\, phase 1\, Biliary Tract Cancer.\nStudy: Chemoimmun
 otherapy Combined With Hyperthermia and Spatially-Fractionated Radiotherap
 y in Advanced Biliary Tract Cancer\nEstimated primary completion: December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0654696
 9
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06710223-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 1 readout est. (NCT06710223)
DESCRIPTION:Durvalumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Cryoab
 lation and Arterial Infusion of SD-101 in Combination With Durvalumab and 
 Tremelimumab\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06710223
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05582538-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05582538)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Restoring Sensitivity To Immunoth
 erapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Pr
 iming Followed By Combined Durvalumab/Nab-Paclitaxel\nEstimated primary co
 mpletion: December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05582538
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04472949-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04472949)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Thoracic
  Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and
  Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Canc
 er (ED-SCLC).\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04472949
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733598-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05733598)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Study 
 of RP2 in Combination With Second-line Therapy in Patients With Locally Ad
 vanced or Metastatic HCC\nEstimated primary completion: 1 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05733598
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05795101-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05795101)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: TRUDI: TDXD+Durva in HER2+/Low IB
 C\nEstimated primary completion: 1 December 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05795101
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03780608-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03780608)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: A Study of AZD6738 in Combination
  With Durvalumab in Patients With Refractory Solid Tumors (Cohort A: Chemo
 therapy-Refractory Gastric Cancer\; Cohort B: Anti-PD(L)\nEstimated primar
 y completion: 1 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03780608
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06503614-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271222
DTEND;VALUE=DATE:20271223
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06503614)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: A Trial of Durva
 lumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer\nE
 stimated primary completion: 22 December 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06503614
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585477-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04585477)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Adju
 vant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)\n
 Estimated primary completion: 30 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04585477
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02812420-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 1 readout est. (NCT02812420)
DESCRIPTION:Durvalumab\, phase 1\, Urothelial Carcinoma.\nStudy: Durvalumab
  and Tremelimumab in Treating Patients With Muscle-Invasive\, High-Risk Ur
 othelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before
  Surgery\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT02812420
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02726997-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT02726997)
DESCRIPTION:Durvalumab\, phase 1/2\, Ovarian Cancer.\nStudy: Matched Paired
  Pharmacodynamics and Feasibility Study of Durvalumab in Combination With 
 Chemotherapy in Frontline Ovarian Cancer (N-Dur)\nEstimated primary comple
 tion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT02726997
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04728230-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT04728230)
DESCRIPTION:Durvalumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Olapar
 ib and Durvalumab With Carboplatin\, Etoposide\, and/or Radiation Therapy 
 for the Treatment of Extensive-Stage Small Cell Lung Cancer\, PRIO Trial\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04728230
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Study of Precision Treatment for 
 Rare Tumours in China Guided by PDO and NGS\nEstimated primary completion:
  31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/du
 rvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06692491
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05632809-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05632809)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: REStoring lymphoCytes Using NKTR-
 255* After chemoradiothErapy in Solid Tumors (RESCUE)\nEstimated primary c
 ompletion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05632809
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07780838-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07780838)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Alternating Chem
 o-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangioc
 arcinoma\nEstimated primary completion: 31 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07780838
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07235007-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Durvalumab: Phase na readout est. (NCT07235007)
DESCRIPTION:Durvalumab\, phase na.\nStudy: Repeated Endobiliary Radiofreque
 ncy Ablation Plus Durvalumab\, Gemcitabine\, and Cisplatin for Unresectabl
 e Extrahepatic Cholangiocarcinoma\nEstimated primary completion: 31 Decemb
 er 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07235
 007
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02029001-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT02029001)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Adapting Treatment to the Tumor M
 olecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecifi
 cTreatment\nEstimated primary completion: January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT02029001
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04105270-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04105270)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: RMT 
 in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. 
 A Randomized Double Blind Phase II Trial\nEstimated primary completion: Ja
 nuary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvaluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 105270
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04644289-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04644289)
DESCRIPTION:Durvalumab\, phase 2\, Ovarian Cancer.\nStudy: WoO: Window of O
 pportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC\n
 Estimated primary completion: January 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04644289
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06464068-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06464068)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: AGNOSTIC THERAPY IN A PHASE II SI
 NGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH C
 ARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE ST
 AGE - EXTRAPULMONARY SMALL CELL CARCINOMA\nEstimated primary completion: 1
  January 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durval
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06464068
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880523-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06880523)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: STRIDE
  (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectab
 le Hepatocellular Carcinoma\nEstimated primary completion: 31 January 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06880523
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226063-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07226063)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Mainte
 nance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocel
 lular Cancer\nEstimated primary completion: February 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07226063
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06954480-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06954480)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Investigating Datopotamab Deruxte
 can Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-ne
 gative Metastatic Triple-negative Breast Cancer\nEstimated primary complet
 ion: February 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 urvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06954480
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05617963-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05617963)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung C
 ancer Patients Whose Disease is Limited to the Thorax\nEstimated primary c
 ompletion: 24 February 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05617963
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653438-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07653438)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: In V
 ivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients Wi
 th Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemora
 diotherapy\nEstimated primary completion: 1 March 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07653438
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911255-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06911255)
DESCRIPTION:Durvalumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Safe
 ty and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable 
 Hepatocellular Carcinoma\nEstimated primary completion: 31 March 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06911255
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05034887-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05034887)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Phase 2 Study of Trastuzumab Deru
 xtecan in the Neoadjuvant Treatment\, or Trastuzumab Deruxtecan Plus Capec
 itabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Ad
 juvant Treatment for Patients With HER2 Positive Gastric and Gastroesophag
 eal Junction Adenocarcinoma\nEstimated primary completion: 31 March 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05034887
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03682289-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03682289)
DESCRIPTION:Durvalumab\, phase 2\, Urothelial Carcinoma.\nStudy: Ceralasert
 ib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patie
 nts With Solid Tumors\nEstimated primary completion: 31 March 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03682289
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963346-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Durvalumab: Phase 1 readout est. (NCT06963346)
DESCRIPTION:Durvalumab\, phase 1\, Bladder Cancer.\nStudy: Study Investigat
 ing Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Ag
 ents\nEstimated primary completion: April 2028. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06963346
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07146230-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07146230)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: The 
 Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small 
 Cell Lung Cancer Trial 2\nEstimated primary completion: April 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07146230
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07531095-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280521
DTEND;VALUE=DATE:20280522
SUMMARY:Durvalumab: Phase 1 readout est. (NCT07531095)
DESCRIPTION:Durvalumab\, phase 1\, Small Cell Lung Cancer.\nStudy: Study of
  Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in S
 mall Cell Lung Cancer (SCLC)\nEstimated primary completion: 21 May 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07531095
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05932199-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT05932199)
DESCRIPTION:Durvalumab\, phase 1/2.\nStudy: Neoadjuvant Durvalumab and Trem
 elimumab With and Without Chemotherapy for Mesothelioma\nEstimated primary
  completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05932199
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680050-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06680050)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phas
 e II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stag
 e III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACI
 FIC Regimen\nEstimated primary completion: June 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06680050
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03539822-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03539822)
DESCRIPTION:Durvalumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Cabo
 zantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gas
 troesophageal Cancer and Other Gastrointestinal Malignancies\nEstimated pr
 imary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03539822
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031233-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Durvalumab: Phase 4 readout est. (NCT06031233)
DESCRIPTION:Durvalumab\, phase 4.\nStudy: Evaluating the Safety of Shortene
 d Infusion Times for dIfferent Oncological Immunotherapie\nEstimated prima
 ry completion: July 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06031233
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673341-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07673341)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: [18F]FTT Positron Emission Tomogr
 aphy/Computed Tomography to Predict Treatment Response in Patients Schedul
 ed to Receive Gemcitabine\, Cisplatin\, and Durvalumab for Newly Diagnosed
  Cholangiocarcinoma\nEstimated primary completion: 1 July 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07673341
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04430452-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04430452)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durval
 umab With/Without Tremelimumab After Palliative Hypofractionated Radiother
 apy for Hepatocellular Carcinoma\nEstimated primary completion: 31 July 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04430452
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06960577-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06960577)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: Perioperative Du
 rvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder 
 Cancer (NIAGARA-2)\nEstimated primary completion: 30 August 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06960577
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05137262-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05137262)
DESCRIPTION:Durvalumab\, phase 2\, Bladder Cancer.\nStudy: A Phase II Multi
 center Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 473
 6) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladde
 r\nEstimated primary completion: 31 August 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05137262
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06393816-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06393816)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: FIRST-NEC (GFPC 01-2022) - Combin
 ation of Durvalumab With Etoposide and Platinum\nEstimated primary complet
 ion: September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06393816
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07757191-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07757191)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: DURATION-GC: FLOT Plus Durvalumab
  and TS-1 Plus Durvalumab for Resectable Gastric Cancer\nEstimated primary
  completion: September 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07757191
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06027086-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06027086)
DESCRIPTION:Durvalumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: DRP-
 104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With
  Advanced Stage Fibrolamellar Carcinoma (FLC)\nEstimated primary completio
 n: 1 September 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06027086
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288034-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281008
DTEND;VALUE=DATE:20281009
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07288034)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Immu
 notherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Resp
 onse and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cel
 l Lung Cancer\, IMMUNO-BIOMAP Trial\nEstimated primary completion: 8 Octob
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07288
 034
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06551142-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281016
DTEND;VALUE=DATE:20281017
SUMMARY:Durvalumab: Phase 1 readout est. (NCT06551142)
DESCRIPTION:Durvalumab\, phase 1.\nStudy: A Study of GSK5764227 in Particip
 ants With Advanced Solid Tumors (EMBOLD)\nEstimated primary completion: 16
  October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durval
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06551142
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06630130-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06630130)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Perioperative Therapies in Locall
 y Advanced Unresectable Gastric Cancer\nEstimated primary completion: 30 O
 ctober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6630130
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03833154-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT03833154)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Durv
 alumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBR
 T in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ O
 simertinib Following SBRT in Patients With Early Stage Unresected NSCLC Ha
 rboring an EGFR Mutation\nEstimated primary completion: 31 October 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03833154
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07036380-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07036380)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: MP0317 in Combination With Chemoi
 mmunotherapy in First Line Treatment for Patients With Advanced Biliary Tr
 act Carcinoma\nEstimated primary completion: November 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07036380
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858735-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281119
DTEND;VALUE=DATE:20281120
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06858735)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: HYPERION CCA: a Phase 2 Trial of 
 Systemic Therapy With or Without Liver-directed Radiation Therapy for Pati
 ents With Advanced Intrahepatic Cholangiocarcinoma\nEstimated primary comp
 letion: 19 November 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06858735
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112379-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281120
DTEND;VALUE=DATE:20281121
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06112379)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: A Phase III Randomised Study to E
 valuate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Trip
 le-Negative or Hormone Receptor-low/HER2-negative Breast Cancer\nEstimated
  primary completion: 20 November 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06112379
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06746116-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06746116)
DESCRIPTION:Durvalumab\, phase 3\, Endometrial Cancer.\nStudy: A Study to E
 valuate the Use of Durvalumab in Combination With Platinum-based Chemother
 apy Followed by Durvalumab With Olaparib as First-line Treatment in Advanc
 ed or Recurrent Endometrial Cancer in Spain\nEstimated primary completion:
  30 November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/du
 rvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06746116
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06282575-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06282575)
DESCRIPTION:Durvalumab\, phase 3\, Biliary Tract Cancer.\nStudy: Efficacy a
 nd Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of
 -care Therapy for Advanced HER2-positive Biliary Tract Cancer\nEstimated p
 rimary completion: 1 December 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06282575
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07941609-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281216
DTEND;VALUE=DATE:20281217
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07941609)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Investigate the Efficacy and Safety of Dato-DXd-based Combinations 
 in Participants With TROP2 NMR+ NSCLC\nEstimated primary completion: 16 De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7941609
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492408-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06492408)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoadj
 uvant Intra-tumor Double Immunotherapy for Hepatocellular Carcinoma.\nEsti
 mated primary completion: 30 December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06492408
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06492421-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281230
DTEND;VALUE=DATE:20281231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06492421)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Intra-tumor Double Immunotherapy for Lung Cancer.\nEstimated prima
 ry completion: 30 December 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06492421
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03317158-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03317158)
DESCRIPTION:Durvalumab\, phase 1/2\, Bladder Cancer.\nStudy: Modern Immunot
 herapy in BCG-Unresponsive\, BCG-Relapsing and High Risk BCG-Naive Non-Mus
 cle Invasive Urothelial Carcinoma of the Bladder\nEstimated primary comple
 tion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT03317158
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06769126-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06769126)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Using Bi
 omarker Tests to Select and Test New\, Personalized Treatments for Extensi
 ve Stage Small Cell Lung Cancer\, PRISM Study\nEstimated primary completio
 n: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06769126
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988945-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04988945)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: TACE a
 nd SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Ca
 rcinoma\nEstimated primary completion: 31 December 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04988945
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06667908-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06667908)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy of JNJ-90301900 in Combination With Chemoradiation Followed by Consoli
 dation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)\nEstimated pri
 mary completion: 31 December 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06667908
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04092283-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT04092283)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Test
 ing the Addition of an Antibody to Standard Chemoradiation Followed by the
  Antibody for One Year to Standard Chemoradiation Followed by One Year of 
 the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung C
 ancer\nEstimated primary completion: 31 December 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04092283
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005128-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Durvalumab: Phase 3 readout est. (NCT07005128)
DESCRIPTION:Durvalumab\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study 
 Comparing Tarlatamab\, Durvalumab\, Carboplatin\, and Etoposide Versus Dur
 valumab\, Carboplatin\, and Etoposide in First-line Extensive Stage Small-
 Cell Lung Cancer (ES-SCLC)\nEstimated primary completion: 4 January 2029. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07005128
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07876817-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Durvalumab: Phase 4 readout est. (NCT07876817)
DESCRIPTION:Durvalumab\, phase 4\, Bladder Cancer.\nStudy: A Prospective\, 
 Multi-Center\, Phase 4\, Single Arm Study To Assess The Safety and Tolerab
 ility of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitab
 ine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer 
 Cle-Invasive\nEstimated primary completion: 31 January 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07876817
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149363-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07149363)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Adjuvant
  Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Ca
 ncer\nEstimated primary completion: February 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07149363
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339059-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07339059)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Study of
  Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy
  for Extensive-Stage Small Cell Lung Cancer\nEstimated primary completion:
  1 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dur
 valumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07339059
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06780137-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290215
DTEND;VALUE=DATE:20290216
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06780137)
DESCRIPTION:Durvalumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Stud
 y to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatama
 b Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-St
 age Small Cell Lung Cancer (MK-6070-002)\nEstimated primary completion: 15
  February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durva
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06780137
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564623-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Durvalumab: Phase 1 readout est. (NCT06564623)
DESCRIPTION:Durvalumab\, phase 1\, Biliary Tract Cancer.\nStudy: Targeting 
 Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab f
 or Patients With Biliary Tract Cancers (BTC)\nEstimated primary completion
 : March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06564623
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07625930-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07625930)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: RESTAGE (REpurposing STAtins to I
 mprove Outcomes in GastroEsophageal Cancer) Trial\nEstimated primary compl
 etion: April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/du
 rvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07625930
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06078709-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290525
DTEND;VALUE=DATE:20290526
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06078709)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Preoperative Hypofractionated Rad
 iotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocar
 cinoma\nEstimated primary completion: 25 May 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06078709
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06992609-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06992609)
DESCRIPTION:Durvalumab\, phase 3\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.\nEstim
 ated primary completion: 30 June 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06992609
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174583-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT07174583)
DESCRIPTION:Durvalumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: A Stud
 y of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell L
 ung Cancer\nEstimated primary completion: July 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07174583
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06214572-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290721
DTEND;VALUE=DATE:20290722
SUMMARY:Durvalumab: Phase 2/3 readout est. (NCT06214572)
DESCRIPTION:Durvalumab\, phase 2/3\, Bladder Cancer.\nStudy: Radiation Ther
 apy in Unresectable Gall Bladder Cancer\nEstimated primary completion: 21 
 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT062
 14572
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06287775-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290725
DTEND;VALUE=DATE:20290726
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT06287775)
DESCRIPTION:Durvalumab\, phase 1/2\, Small Cell Lung Cancer.\nStudy: Testin
 g the Combination of an Anti-cancer Drug\, Iadademstat\, With Other Anti-c
 ancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small C
 ell Lung Cancer\nEstimated primary completion: 25 July 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06287775
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07055581-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07055581)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: Durvalum
 ab as Consolidation for Patients LS-SCLC\nEstimated primary completion: 31
  July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvaluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 055581
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459634-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290804
DTEND;VALUE=DATE:20290805
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07459634)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study 
 of Lurbinectedin in Combination With Durvalumab for the Treatment of Parti
 cipants With ES-SCLC\nEstimated primary completion: 4 August 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07459634
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07168668-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290814
DTEND;VALUE=DATE:20290815
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07168668)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Partial Immune-boost TACE in unrE
 seCTable HCC Patients Under Systemic Treatment\nEstimated primary completi
 on: 14 August 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 urvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07168668
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUIL
 T-3.055: A Study of Combination Immunotherapies in Patients Who Have Previ
 ously Received Treatment With Immune Checkpoint Inhibitors\nEstimated prim
 ary completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07269158-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT07269158)
DESCRIPTION:Durvalumab\, phase 1/2\, Biliary Tract Cancer.\nStudy: A Phase 
 IIb Randomized Clinical Trial of Immune Checkpoint Inhibitor-based Mainten
 ance Therapy in Patients With Advanced Biliary Tract Cancer\nEstimated pri
 mary completion: September 2029. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07269158
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904170-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290914
DTEND;VALUE=DATE:20290915
SUMMARY:Durvalumab: Phase 2/3 readout est. (NCT06904170)
DESCRIPTION:Durvalumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemo
 therapy in Hepatocellular Carcinoma\nEstimated primary completion: 14 Sept
 ember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvaluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 904170
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04892953-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Durvalumab: Phase 2 readout est. (NCT04892953)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Loca
 l Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogre
 ssive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy\nEstimat
 ed primary completion: 30 September 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04892953
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284317-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06284317)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A St
 udy to Evaluate the Benefit of Adding Durvalumab After Chemotherapy\, Durv
 alumab and Surgery in Patients With Early-stage\, Operable\, Non-small Cel
 l Lung Cancer.\nEstimated primary completion: October 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06284317
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187338-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT05187338)
DESCRIPTION:Durvalumab\, phase 1/2.\nStudy: Triplex Checkpoint Inhibitors T
 herapy for Advanced Solid Tumors\nEstimated primary completion: 30 October
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0518733
 8
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05903092-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05903092)
DESCRIPTION:Durvalumab\, phase 2\, Small Cell Lung Cancer.\nStudy: MOnaliZu
 mab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell
  Lung Cancer\nEstimated primary completion: 31 October 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05903092
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877818-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Durvalumab: Phase 3 readout est. (NCT07877818)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: A Study of Neoadjuvant-adjuvant D
 urvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese
  Patients With Resectable GC/GEJC.\nEstimated primary completion: 1 Novemb
 er 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07877
 818
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810609-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06810609)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Immu
 nochemotherapy\, Surgery or Chemoradiation\, and Durvalumab for Stage IIIA
 /B NSCLC\nEstimated primary completion: 31 December 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06810609
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911280-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07911280)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: A Phase II\, Trial of Neoadjuvant
  Trastuzumab + Durvalumab + FLOT Targeted Immunochemotherapy\nEstimated pr
 imary completion: 1 January 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07911280
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05255653-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Durvalumab: Phase 3 readout est. (NCT05255653)
DESCRIPTION:Durvalumab\, phase 3\, Endometrial Cancer.\nStudy: Refining Adj
 uvant Treatment IN Endometrial Cancer Based On Molecular Features\nEstimat
 ed primary completion: 1 January 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05255653
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07122089-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300102
DTEND;VALUE=DATE:20300103
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07122089)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Evalua
 tion of SIRT Followed by Immunotherapy for Treatment of Hepatocellular Car
 cinoma With Portal Vein Thrombosis\nEstimated primary completion: 2 Januar
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071220
 89
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07507968-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300201
DTEND;VALUE=DATE:20300202
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07507968)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: TNT With FLOT/Durvalumab Plus Pos
 t-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma\nEstimated 
 primary completion: 1 February 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07507968
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07872722-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07872722)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Zolbetuximab\, Durvalumab\, and F
 LOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Can
 cer or Gastroesophageal Junction Adenocarcinoma\nEstimated primary complet
 ion: 31 March 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 urvalumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07872722
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489976-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07489976)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: IIT2025-03-YANG-LIFT-HCC\nEstimat
 ed primary completion: 1 April 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07489976
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03011814-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300414
DTEND;VALUE=DATE:20300415
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03011814)
DESCRIPTION:Durvalumab\, phase 1/2.\nStudy: Durvalumab With or Without Lena
 lidomide in Treating Patients With Relapsed or Refractory Cutaneous or Per
 ipheral T Cell Lymphoma\nEstimated primary completion: 14 April 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03011814
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03847649-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Durvalumab: Phase 2 readout est. (NCT03847649)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: A Phase II Study of Durvalumab Tr
 eatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therap
 y Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/
 - Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies\
 nEstimated primary completion: 30 April 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03847649
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05061550-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300528
DTEND;VALUE=DATE:20300529
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05061550)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer\nE
 stimated primary completion: 28 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05061550
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05361395-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300530
DTEND;VALUE=DATE:20300531
SUMMARY:Durvalumab: Phase 1 readout est. (NCT05361395)
DESCRIPTION:Durvalumab\, phase 1\, Small Cell Lung Cancer.\nStudy: First-Li
 ne Tarlatamab in Combination With Carboplatin\, Etoposide\, and PD-L1 Inhi
 bitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)\nE
 stimated primary completion: 30 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05361395
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999707-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06999707)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Photon
  Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC\nEst
 imated primary completion: 31 May 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06999707
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999694-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06999694)
DESCRIPTION:Durvalumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Proton
  Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC\nEst
 imated primary completion: 31 May 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06999694
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107750-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Durvalumab: Phase 1 readout est. (NCT07107750)
DESCRIPTION:Durvalumab\, phase 1\, Biliary Tract Cancer.\nStudy: Emavuserti
 b (CA-4948) in Combination With Cisplatin\, Gemcitabine\, and Durvalumab i
 n Patients With Untreated Advanced or Metastatic Biliary Tract Cancer\nEst
 imated primary completion: 30 June 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07107750
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03942328-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20300831
DTEND;VALUE=DATE:20300901
SUMMARY:Durvalumab: Phase 1/2 readout est. (NCT03942328)
DESCRIPTION:Durvalumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Modi
 fied Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Com
 bined With Immune Checkpoint Inhibition After High-Dose External Beam Radi
 ation Therapy in Treating Patients With Unresectable Liver Cancer\nEstimat
 ed primary completion: 31 August 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03942328
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Durvalumab: Phase 2 readout est. (NCT01042379)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuvant and Pers
 onalized Adaptive Novel Agents to Treat Breast Cancer\nEstimated primary c
 ompletion: December 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/durvalumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT01042379
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07639528-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20301210
DTEND;VALUE=DATE:20301211
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07639528)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Preoperative Durvalumab\, Cisplat
 in\, Gemcitabine With or Without Futibatinib Targeted Therapy for the Trea
 tment of Resectable Intrahepatic Cholangiocarcinoma\, OPTIC Trial\nEstimat
 ed primary completion: 10 December 2030. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07639528
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06898957-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20310623
DTEND;VALUE=DATE:20310624
SUMMARY:Durvalumab: Phase 1 readout est. (NCT06898957)
DESCRIPTION:Durvalumab\, phase 1\, Small Cell Lung Cancer.\nStudy: Study of
  Tarlatamab in Combination With YL201 With or Without Anti-programmed Deat
 h Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lu
 ng Cancer (SCLC)\nEstimated primary completion: 23 June 2031. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06898957
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05253131-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20311115
DTEND;VALUE=DATE:20311116
SUMMARY:Durvalumab: Phase 2 readout est. (NCT05253131)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Trial of Selumetinib and Bromodom
 ain Inhibitor With Durvalumab for Sarcomas\nEstimated primary completion: 
 15 November 2031. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dur
 valumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05253131
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07247786-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20311230
DTEND;VALUE=DATE:20311231
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07247786)
DESCRIPTION:Durvalumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stud
 y for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant
  in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)\n
 Estimated primary completion: 30 December 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07247786
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06058377-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06058377)
DESCRIPTION:Durvalumab\, phase 3.\nStudy: Adding an Immunotherapy Drug\, ME
 DI4736 (Durvalumab)\, to the Usual Chemotherapy Treatment (Paclitaxel\, Cy
 clophosphamide\, and Doxorubicin) for Stage II-III Breast Cancer\nEstimate
 d primary completion: 31 May 2032. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06058377
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680739-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20320701
DTEND;VALUE=DATE:20320702
SUMMARY:Durvalumab: Phase 2 readout est. (NCT06680739)
DESCRIPTION:Durvalumab\, phase 2\, Endometrial Cancer.\nStudy: Single cEll 
 pRofiling PErsistaNce To ImmuNothErapy\nEstimated primary completion: 1 Ju
 ly 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06680
 739
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07766187-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20320831
DTEND;VALUE=DATE:20320901
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07766187)
DESCRIPTION:Durvalumab\, phase 2.\nStudy: Combination Therapy Using Durvalu
 mab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma\nEsti
 mated primary completion: August 2032. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07766187
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07938645-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20330131
DTEND;VALUE=DATE:20330201
SUMMARY:Durvalumab: Phase 2 readout est. (NCT07938645)
DESCRIPTION:Durvalumab\, phase 2\, Biliary Tract Cancer.\nStudy: PARP Inhib
 ition for Biliary Tract Cancer With Mutations in Core and Non-Core Homolog
 ous Recombination Deficiency Genes\nEstimated primary completion: January 
 2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/durvalumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07938645
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06498635-1959@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20390715
DTEND;VALUE=DATE:20390716
SUMMARY:Durvalumab: Phase 3 readout est. (NCT06498635)
DESCRIPTION:Durvalumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Immu
 notherapy After Surgery for People Who Have No Remaining Cancer Cells Afte
 r Standard Treatment for Early-Stage Non-Small Cell Lung Cancer\, INSIGHT 
 Trial\nEstimated primary completion: 15 July 2039. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/durvalumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06498635
URL:https://assetmemo.bio/drug/durvalumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
